Boston Scientific Corporation

1538 articles with Boston Scientific Corporation

• 

  Biopharma Money on the Move: November 25 – December 1

  12/2/2020

  A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.

• Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

  12/1/2020

  Boston Scientific Corporation announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.

• Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference

  11/23/2020

  Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1.

• Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation

  11/17/2020

  Boston Scientific Corporation has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system.

• Boston Scientific Announces November 2020 Conference Schedule

  11/5/2020

  On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president, Investor Relations, will participate in a 40-minute question-and-answer session with the host analyst at the 29th Annual Credit Suisse Virtual Healthcare Conference.

• Boston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon

  11/2/2020

  Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease

• Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke

  10/29/2020

  Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation

• Boston Scientific Announces Results For Third Quarter 2020

  10/28/2020

  Boston Scientific Corporation generated sales of $2.659 billion during the third quarter of 2020.

• Boston Scientific Announces Transcatheter Cardiovascular Therapeutics 2020 Investor Update and Conference Call Discussing Third Quarter 2020 Results

  10/1/2020

   Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT . Joe Fitzgerald , executive vice president and president, Interventional Cardiology; Michael Jaff , D.O., vice president and chief m

• Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In Europe

  9/30/2020

   Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems

• Boston Scientific Launches ACURATE neo2™ Aortic Valve System in Europe

  9/28/2020

  Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior Version

• Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.

  9/21/2020

  Boston Scientific Corporation announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation system for the treatment of atrial fibrillation and other cardiac arrhythmias.

• Boston Scientific Launches Vercise Genus™ DBS System In Europe

  9/9/2020

  Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe

• CMS Grants Additional Reimbursement For The Eluvia™ Drug-Eluting Vascular Stent System

  9/3/2020

  Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System.

• Boston Scientific Announces September 2020 Conference Schedule

  8/26/2020

  Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020 , Mike Mahoney , chairman and chief executive officer, and Susie

• BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation

  7/30/2020

  BioTelemetry, Inc., the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced a sales agent agreement with Boston Scientific, a global medical technology leader.

• Boston Scientific Announces Results For Second Quarter 2020

  7/29/2020

  Boston Scientific Corporation generated sales of $2.003 billion during the second quarter of 2020.

• Boston Scientific Receives FDA Approval for Next-Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

  7/21/2020

  Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

• Michael Enxing joins PainTEQ Board of Directors

  7/1/2020

  PainTEQ, a leading medical device innovator, announced the appointment of Michael Enxing, Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division.

• Boston Scientific Announces Conference Call Discussing Second Quarter 2020 Financial Results

  6/30/2020

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT.